Bristol-Myers Squibb

EC approves BMS cell therapy for multiple myeloma

The European Commission (EC) has approved Bristol Myers Squibb/bluebird bio’s first-in-class anti-B-cell maturation antigen (BCMA) CAR T cell therapy Abecma (idecabtagene vicleucel) for patients with ... battling this incurable disease after exhausting

Gene therapy company bluebird bio quits Europe

At present, only one its therapies, cancer treatment Abecma (marketed in partnership with Bristol Myers Squibb), has received approval in the US.

BMS’ Q2 results beat expectations with strong performance across core therapy areas

Bristol Myers Squibb (BMS) has published its second quarter (Q2) earnings, with revenue for the quarter up by 16% from last year as the company’s strong performance beat expectations.

Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer

This included approvals for not only Keytruda, but also Roche’s Tecentriq (atezolizumab) and Bristol Myers Squibb’s (BMS) Opdivo (nivolumab) in a number of cancer types.

Kite’s CAR-T therapy Yescarta shows positive results in second-line lymphoma study

The positive second-line LBCL Yescarta results follow recently reported data showing success for Bristol Myers Squibb’s (BMS) rival CAR-T therapy Breyanzi in the same patient population and setting.

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]